Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly spliced due to a silent mutation within an exonic splicing enhancer in exon 7. However, correct splicing can be restored by over-expression of the SR-like splicing factor Htra2-beta 1. We show that in fibroblast cultures derived from SMA patients treated with therapeutic doses (0.5-500 microM) of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold. Importantly, this up-regulation of SMN could be most likely attributed to increased levels of Htra2-beta 1 which facilitates the correct splicing of SMN2 RNA as well as to an SMN gene transcription activation. Especially at low VPA concentrations, the restored SMN level depended on the number of SMN2 copies. Moreover, VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats. Finally, VPA also increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing. Since VPA is a drug highly successfully used in long-term epilepsy therapy, our findings open the exciting perspective for a first causal therapy of an inherited disease by elevating the SMN2 transcription level and restoring its correct splicing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P.-A., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,089
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Wirth, B. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200003)15:3<228::aid-humu3>3.0.co;2-9 · Cited by 667
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
Cited by
Items 101–200 of 388
Spinal muscular atrophy: An update on therapeutic progress
Seo, J., Howell, M. D., Singh, N. N., & Singh, R. N. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.005 · Cited by 77
Nissim‐Rafinia, M., Aviram, M., Randell, S. H., Shushi, L., Ozeri, E., Chiba‐Falek, O., Eidelman, O., Pollard, H. B., Yankaskas, J. R., & Kerem, B. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400273 · Cited by 80
Perspectives on Clinical Trials in Spinal Muscular Atrophy
Swoboda, K. J., Kissel, J. T., Crawford, T. O., Bromberg, M. B., Acsádi, G., D’Anjou, G., Krosschell, K. J., Reyna, S. P., Schroth, M. K., Scott, C., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305665 · Cited by 80
Oskoui, M., & Kaufmann, P. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.007 · Cited by 79
Zhou, M., Hu, Z., Qiu, L., Zhou, T., Feng, M., Hu, Q., Zeng, B., Li, Z., Sun, Q., Wu, Y. C., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.255 · Cited by 74
Haastert‐Talini, K., Großkreutz, J., Jaeckel, M., Laderer, C., Bufler, J., Grothe, C., & Claus, P. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.09.003 · Cited by 70
Survival in SMA type I: A prospective analysis of 34 consecutive cases
Cobben, J. M., Lemmink, H. H., Snoeck, I. N., Barth, P. G., van der Lee, J. H., & de Visser, M. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.05.008 · Cited by 68
Expression of Muscle-Specific MiRNA 206 in the Progression of Disease in a Murine SMA Model
Valsecchi, V., Boido, M., Amicis, E. D., Piras, A., & Vercelli, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128560 · Cited by 71
The spliceosome: a novel multi-faceted target for therapy
Tazi, J., Durand, S., & Jeanteur, P. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.06.002 · Cited by 71
Nizzardo, M., Nardini, M., Ronchi, D., Salani, S., Donadoni, C., Fortunato, F., Colciago, G., Falcone, M., Simone, C., Riboldi, G., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.01.017 · Cited by 64
New perspectives of valproic acid in clinical practice
Činčárová, L., Zdráhal, Z., & Fajkus, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.853037 · Cited by 69
Induction of full-length survival motor neuron by polyphenol botanical compounds
Sakla, M. S., & Lorson, C. L. (2007) · Human Genetics · doi:10.1007/s00439-007-0441-0 · Cited by 69
Pathogenesis of proximal autosomal recessive spinal muscular atrophy
Šimić, G. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0411-1 · Cited by 65
Martínez-García, M. Á., Rincón, A., Desviat, L. R., Merinero, B., Ugarte, M., & Pérez, B. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.11.011 · Cited by 63
Mende, Y., Jakubik, M., Rießland, M., Schoenen, F. J., Roßbach, K., Kleinridders, A., Köhler, C. N., Buch, T., & Wirth, B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq094 · Cited by 63
Sleigh, J. N., Buckingham, S. D., Esmaeili, B., Viswanathan, M., Cuppen, E. P. J. G., Westlund, B., & Sattelle, D. B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq459 · Cited by 81
Drug treatment for spinal muscular atrophy types II and III
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub5 · Cited by 79
Update on Biomarkers in Spinal Muscular Atrophy
Pino, M. G., Rich, K. A., & Kolb, S. J. (2021) · Biomarker Insights · doi:10.1177/11772719211035643 · Cited by 70
Substances that can change alternative splice-site selection
Sumanasekera, C., Watt, D. S., & Stamm, S. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360483 · Cited by 61
The effect of hydroxyurea in spinal muscular atrophy cells and patients
Liang, W., Yuo, C., Chang, J., Chen, Y.-C., Chang, Y.-F., Wang, H., Ju, Y., Chiou, S., & Jong, Y. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.11.012 · Cited by 60
Drug treatment for spinal muscular atrophy type I
Wadman, R. I., Bosboom, W. M., van der Pol, W. L., van den Berg, L. H., Wokke, J. H. J., Iannaccone, S. T., & Vrancken, A. F. J. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006281.pub4 · Cited by 64
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
Tsai, L.-K., Tsai, M.-S., Lin, T.-B., Hwu, W.-L., & Li, H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.07.004 · Cited by 58
Arnold, E. S., & Fischbeck, K. H. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00038-7 · Cited by 73
Stat5 constitutive activation rescues defects in spinal muscular atrophy
Ting, C.-H., Lin, C.-W., Wen, S.-L., Hsieh-Li, H.-M., & Li, H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl482 · Cited by 69
Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Citraro, R., Leo, A., Santoro, M., D’agostino, G., Constanti, A., & Russo, E. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666171024130001 · Cited by 57
Venables, J. P., Bourgeois, C. F., Dalgliesh, C., Kister, L., Stévenin, J., & Elliott, D. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi233 · Cited by 61
Thomas, W. B. (2010) · Frontiers in bioscience · doi:10.2741/3670 · Cited by 65
Goulet, B., Kothary, R., & Parks, R. J. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990044 · Cited by 62
Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA
Lorson, M. A., Spate, L. D., Samuel, M., Murphy, C. N., Lorson, C. L., Prather, R. S., & Wells, K. D. (2011) · Transgenic Research · doi:10.1007/s11248-011-9496-8 · Cited by 63
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR
Tiziano, F. D., Pinto, A. M., Fiori, S., Lomastro, R., Messina, S., Bruno, C., Pini, A., Pane, M., D’Amico, A., Ghezzo, A., et al. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.116 · Cited by 54
Kerem, E. (2005) · Pediatric Pulmonology · doi:10.1002/ppul.20200 · Cited by 70
Molecular mechanisms and animal models of spinal muscular atrophy
Edens, B. M., Ajroud‐Driss, S., Ma, L., & Ma, Y. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.07.024 · Cited by 61
VPA response in SMA is suppressed by the fatty acid translocase CD36
Garbes, L., Heesen, L., Hölker, I., Bauer, T., Schreml, J., Zimmermann, K., Thoenes, M., Walter, M. J., Dimos, J. T., Peitz, M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds437 · Cited by 55
Valproic acid treatment in six patients with spinal muscular atrophy
Tsai, L., Yang, C., Hwu, W., & Li, H. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01992.x · Cited by 53
Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy
Mohseni, J. H., Zabidi-Hussin, Z. A. M. H., & Sasongko, T. H. (2013) · Genetics and Molecular Biology · doi:10.1590/s1415-47572013000300001 · Cited by 51
Influence of Friedreich Ataxia GAA Noncoding Repeat Expansions on Pre-mRNA Processing
Baralle, M., Pastor, T., Bussani, E., & Pagani, F. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.018 · Cited by 66
Plastin 3 influences bone homeostasis through regulation of osteoclast activity
Neugebauer, J., Heilig, J., Hosseinibarkooie, S., Ross, B. C., Mendoza-Ferreira, N., Nolte, F., Peters, M., Hölker, I., Hupperich, K., Tschanz, T., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy318 · Cited by 52
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
d’Ydewalle, C. V. O., & Sumner, C. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0337-y · Cited by 57
Survival motor Neuron protein regulates apoptosis in anin vitro model of Spinal muscular atrophy
Parker, G. C., Li, X., Anguelov, R. A., Tóth, G., Cristescu, A., & Acsádi, G. (2008) · Neurotoxicity Research · doi:10.1007/bf03033366 · Cited by 51
Erden, D. D., Bora, G., Ayhan, P., Kocaefe, Ç., Dalkara, S., Yelekçi, K., DEMİR, A. S., & Erdem‐Yurter, H. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00781.x · Cited by 52
Challenges and opportunities in clinical trials for spinal muscular atrophy
Hirtz, D., Iannaccone, S. T., Heemskerk, J., Gwinn, K. A., Moxley, R., & Rowland, L. P. (2005) · Neurology · doi:10.1212/01.wnl.0000183282.10946.c7 · Cited by 50
Hargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 60
van Bergeijk, J., Haastert‐Talini, K., Grothe, C., & Claus, P. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00369.x · Cited by 50
Cherry, J. J., Osman, E. Y., Evans, M. C., Choi, S., Xing, X., Cuny, G. D., Glicksman, M. A., Lorson, C. L., & Androphy, E. J. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202305 · Cited by 53
Lee, J., Horak, C. E., Khanna, C., Meng, Z., Yu, L. R., Veenstra, T. D., & Steeg, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2632 · Cited by 48
Thangapandian, S., John, S., Lee, Y., Kim, S., & Lee, K. W. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12129440 · Cited by 47
Cifuentes-Díaz, C., Frugier, T., & Melki, J. (2002) · Seminars in Pediatric Neurology · doi:10.1053/spen.2002.33801 · Cited by 46
Hsu, S., Lai, M., Er, T., Yang, S., Hung, C., Tsai, H., Lin, Y., Chang, J., Lo, Y., & Jong, Y. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.035 · Cited by 49
Pre-mRNA Missplicing as a Cause of Human Disease
Novoyatleva, T., Tang, Y., Rafalska, I., & Stamm, S. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_2 · Cited by 55
Tazi, J., Bakkour, N., Soret, J., Zekri, L., Hazra, B., Laine, W., Baldeyrou, B., Lansiaux, A., & Bailly, C. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007633 · Cited by 44
Spinal Muscular Atrophy and Therapeutic Prospects
Wirth, B., Brichta, L., & Hahnen, E. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_6 · Cited by 44
Self-citationAlternative splicing interference by xenobiotics
Zaharieva, E. E., Chipman, J. K., & Soller, M. (2012) · Toxicology · doi:10.1016/j.tox.2012.01.014 · Cited by 58
Darbar, I. A., Plaggert, P. G., de Resende, M. B. D., Zanoteli, E., & Reed, U. C. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-36 · Cited by 44
Discovery, Synthesis, and Biological Evaluation of Novel SMN Protein Modulators
Xiao, J., Marugán, J., Zheng, W., Titus, S., Southall, N. T., Cherry, J. J., Evans, M., Androphy, E. J., & Austin, C. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200497t · Cited by 45
Induced pluripotent stem cells for modeling neurological disorders
Russo, F. B., Cugola, F. R., Fernandes, I. R., Pignatari, G. C., & Beltrão-Braga, P. C. B. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i4.209 · Cited by 48
Smeriglio, P., Langard, P., Querin, G., & Biferi, M. G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030075 · Cited by 51
Lin, Y., Ho, T., Lin, T., Hsu, W.-Y., Huang, S., Liao, C., Lai, C., Liu, X., Tsang, H., Lai, C., et al. (2015) · Biomedicine · doi:10.7603/s40681-015-0010-0 · Cited by 45
Tiziano, F. D., Lomastro, R., Pietro, L. D., Pasanisi, M. B., Fiori, S., Angelozzi, C., Abiusi, E., Angelini, C. I., Sorarú, G., Gaiani, A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.233 · Cited by 42
When proteins start to make sense: fine-tuning of aminoglycosides for PTC suppression therapy
Shalev, M., & Baasov, T. (2014) · MedChemComm · doi:10.1039/c4md00081a · Cited by 48
Zheleznyakova, G. Y., Kiselev, A., Vakharlovsky, V. G., Rask‐Andersen, M., Chavan, R. A., Egorova, A., Schiöth, H. B., & Баранов, В. С. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-96 · Cited by 42
Malignant glioma—induced neuronal cell death in an organotypic glioma invasion model
Eyüpoglu, I. Y., Hahnen, E., Heckel, A., Siebzehnrübl, F. A., Buslei, R., Fahlbusch, R., & Blümcke, I. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.4.0738 · Cited by 45
Fuller, H. R., Mân, N. T., Lam, L. T., Shamanin, V. A., Androphy, E. J., & Morris, G. E. (2010) · Journal of Proteome Research · doi:10.1021/pr1005263 · Cited by 41
A feasibility study for the newborn screening of spinal muscular atrophy
Pyatt, R. E., & Prior, T. W. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000227970.60450.b2 · Cited by 41
Robust quantification of the SMN gene copy number by real-time TaqMan PCR
Gómez-Curet, I., Robinson, K. G., Funanage, V. L., Crawford, T. O., Scavina, M. T., & Wang, W. (2007) · Neurogenetics · doi:10.1007/s10048-007-0093-1 · Cited by 44
Phosphatidylserine Increases IKBKAP Levels in Familial Dysautonomia Cells
Keren, H., Donyo, M., Zeevi, D., Maayan, C., Pupko, T., & Ast, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015884 · Cited by 40
Pagliarini, V., Guerra, M., Rosa, V. D., Compagnucci, C., & Sette, C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14935 · Cited by 46
Piepers, S., Cobben, J. M., Sodaar, P., Jansen, M., Wadman, R. I., Meester‐Delver, A., Poll‐The, B. T., Lemmink, H. H., Wokke, J. H. J., van der Pol, W. L., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.200253 · Cited by 39
Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy
Cherry, J. J., Kobayashi, D. T., Lynes, M. M., Naryshkin, N. N., Tiziano, F. D., Zaworski, P. G., Rubin, L. L., & Jarecki, J. (2014) · Assay and Drug Development Technologies · doi:10.1089/adt.2014.587 · Cited by 43
Maretina, M. A., Zheleznyakova, G. Y., Lanko, K., Egorova, A., Баранов, В. С., & Kiselev, A. (2018) · Current Genomics · doi:10.2174/1389202919666180101154916 · Cited by 48
Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA
Simard, L. R., Bélanger, M.-C., Morissette, S., Wride, M. C., Prior, T. W., & Swoboda, K. J. (2007) · Neurology · doi:10.1212/01.wnl.0000252934.70676.ab · Cited by 41
Mutsaers, C. A., Lamont, D. J., Hunter, G., Wishart, T. M., & Gillingwater, T. H. (2013) · Genome Medicine · doi:10.1186/gm498 · Cited by 48
Yuo, C., Lin, H., Chang, Y., Yang, W., & Chang, J. (2007) · Annals of Neurology · doi:10.1002/ana.21241 · Cited by 37
Harahap, I. S. K., Saito, T., San, L. P., Sasaki, N., Gunadi, G., Nurputra, D. K., Yusoff, S., Yamamoto, T., Morikawa, S., Nishimura, N., et al. (2011) · Brain and Development · doi:10.1016/j.braindev.2011.04.010 · Cited by 38
The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy
Lunke, S., & El‐Osta, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06084.x · Cited by 39
Vézain, M., Saugier-Véber, P., Melki, J., Toutain, A., Bieth, É., Husson, M., Pedespan, J., Viollet, L., Pénisson-Besnier, I., Fehrenbach, S., et al. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201885 · Cited by 37
Singh, J., Khan, M., & Singh, I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m017491 · Cited by 37
SMN-Inducing Compounds For The Treatment Of Spinal Muscular Atrophy
Lorson, M. A., & Lorson, C. L. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.131 · Cited by 37
Spontaneous In Vitro Transformation of Adult Neural Precursors into Stem‐Like Cancer Cells
Siebzehnrübl, F. A., Jeske, I., Müller, D., Buslei, R., Coras, R., Hahnen, E., Huttner, H. B., Corbeil, D., Kaesbauer, J., Appl, T., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00189.x · Cited by 42
Miller‐Kasprzak, E., & Jagodziński, P. P. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.07.015 · Cited by 41
Storbeck, M., Hupperich, K., Gaspar, J. A., Meganathan, K., Carrera, L. M., Wirth, R., Sachinidis, A., & Wirth, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089020 · Cited by 34
Spinal muscular atrophy: diagnosis, treatment and future prospects
Baioni, M. T. C., & Ambiel, C. R. (2010) · Jornal de Pediatria · doi:10.2223/jped.1988 · Cited by 51
Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0059 · Cited by 34
Clinical trials in spinal muscular atrophy
Darras, B. T., & Kang, P. B. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3282f1884c · Cited by 34
Bian, Y., Masuda, A., Matsuura, T., Ito, M., Okushin, K., Engel, A. G., & Ohno, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp023 · Cited by 33
Lai, J., Leman, L. J., Ku, S., Vickers, C. J., Olsen, C. A., Montero, A., Ghadiri, M. R., & Gottesfeld, J. M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.027 · Cited by 36
A novel cell immunoassay to measure survival of motor neurons protein in blood cells
Kolb, S. J., Gubitz, A. K., Olszewski, R. F., Ottinger, E. A., Sumner, C. J., Fischbeck, K. H., & Dreyfuss, G. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-6 · Cited by 33
Darras, B. T., Markowitz, J. A., Monani, U. R., & Vivo, D. C. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00008-1 · Cited by 48
Wang, J., Michelhaugh, S. K., & Bannon, M. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05460.x · Cited by 33
Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors
Carré, A., & Empey, C. (2015) · Journal of Genetic Counseling · doi:10.1007/s10897-015-9859-z · Cited by 38
Induction of Neurotrophic and Differentiation Factors in Neural Stem Cells by Valproic Acid
Almutawa, W., Kang, N. H., Pan, Y., & Niles, L. P. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12201 · Cited by 38
Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses
Kobayashi, D. T., Olson, R. J., Sly, L. M., Swanson, C. J., Chung, B., Naryshkin, N. A., Narasimhan, J., Bhattacharyya, A., Mullenix, M. C., & Chen, K. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024269 · Cited by 31
Stem Cell Model of Spinal Muscular Atrophy
Ebert, A. D., & Svendsen, C. N. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.89 · Cited by 30
Increased expression of splicing factor SRp20 mRNA in bipolar disorder patients
Watanuki, T., Funato, H., Uchida, S., Matsubara, T., Kobayashi, A., Wakabayashi, Y., Otsuki, K., Nishida, A., & Watanabe, Y. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.003 · Cited by 40
A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy
Mân, N. T., Humphrey, E., Lam, L. T.-M., Fuller, H. R., Lynch, T., Sewry, C. A., Goodwin, P. R., MacKenzie, A., & Gm, M. (2008) · Neurology · doi:10.1212/01.wnl.0000313038.34337.b1 · Cited by 31
Also‐Rallo, E., Alías, L., Martínez‐Hernández, R., Caselles, L., Barceló, M. J., Baiget, M., Bernal, S., & Tizzano, E. F. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.89 · Cited by 30
Repair of pre-mRNA splicing: Prospects for a therapy for spinal muscular atrophy
Nlend, R. N., Meyer, K., & Schümperli, D. (2010) · RNA Biology · doi:10.4161/rna.7.4.12206 · Cited by 34
Alternative Splicing: Therapeutic Target and Tool
García-Blanco, M. A. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_3 · Cited by 30
Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein
Anderton, R. S., Meloni, B. P., Mastaglia, F. L., & Boulos, S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8399-5 · Cited by 38
Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy
Butchbach, M. E. R., Lumpkin, C. J., Harris, A. W., Saieva, L., Edwards, J. D., Workman, E., Simard, L. R., Pellizzoni, L., & Burghes, A. H. M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.009 · Cited by 33
Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I
Krosschell, K. J., Kissel, J. T., Townsend, E. L., Simeone, S. D., Zhang, R. Z., Reyna, S. P., Crawford, T. O., Schroth, M. K., Acsádi, G., Kishnani, P. S., et al. (2017) · Muscle & Nerve · doi:10.1002/mus.25776 · Cited by 30
Metadata
- Authors
- Brichta, L.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Brichta, L.
- ORCID
- Brichta, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2481-2489
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151318390
- Cited by
- 382
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 15 · 2013: 31 · 2012: 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- valproic acid, spinal muscular atrophy, SMN2, SMN1, SR proteins, alternative splicing, exonic splicing enhancers, drug repurposing, inherited neuromuscular disease
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Exons, Fibroblasts, Gene Expression Regulation, Hippocampus, Humans, Muscular Atrophy, Spinal, Nerve Tissue Proteins, Organ Culture Techniques, RNA Splicing, RNA, Messenger, Time Factors, Transcription, Genetic, Valproic Acid, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Deletion, GABA Agents, Reverse Transcriptase Polymerase Chain Reaction, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.